<?xml version="1.0" encoding="UTF-8"?>
<p>In 2017, the U.S. Food and Drug Administration approved TCZ for the treatment of cytokine release syndrome (CRS) consisting in a systemic inflammatory response caused by the massive release of pro-inflammatory cytokines in response to iatrogenic (
 <italic>e.g.</italic> CAR-t therapies) or infective stimuli.
</p>
